Trial Profile
A Phase 1 Study of MLN8237 in Japanese Patients with Relapsed and/or Refractory Non-Hodgkin's lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Jun 2016
Price :
$35
*
At a glance
- Drugs Alisertib (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Takeda
- 08 Jun 2016 New trial record